Title: Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women
Authors: LaCroix, Andrea Z ×
Powles, Trevor
Osborne, C Kent
Wolter, Kevin
Thompson, John R
Thompson, David D
Allred, D Craig
Armstrong, Róisín
Cummings, Steve R
Eastell, Richard
Ensrud, Kristine E
Goss, Paul
Lee, Andrew
Neven, Patrick
Reid, David M
Curto, Madelyn
Vukicevic, Slobodan
PEARL Investigators #
Issue Date: Nov-2010
Publisher: Oxford University Press
Series Title: Journal of the National Cancer Institute vol:102 issue:22 pages:1706-15
Abstract: Currently available selective estrogen receptor modulators reduce the risk of breast cancer, but they are not widely used. In the Postmenopausal Evaluation and Risk-Reduction with Lasofoxifene (PEARL) trial, lasofoxifene was shown to reduce the risk of estrogen receptor-positive (ER+) breast cancer, nonvertebral and vertebral fractures, coronary artery disease, and stroke, but the effects on total breast cancer (invasive and ductal carcinoma in situ, ER+ and estrogen receptor-negative [ER-]) and ER+ invasive breast cancer are unknown.
ISSN: 0027-8874
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Gynaecological Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science